Compare RGP & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGP | TLSA |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | 10 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.0M | 155.3M |
| IPO Year | 2000 | 2017 |
| Metric | RGP | TLSA |
|---|---|---|
| Price | $4.71 | $1.16 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 313.6K | 258.1K |
| Earning Date | 04-08-2026 | 05-04-2026 |
| Dividend Yield | ★ 6.85% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $551,331,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.06 | $1.08 |
| 52 Week High | $6.07 | $2.60 |
| Indicator | RGP | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 61.95 | 37.47 |
| Support Level | $4.21 | N/A |
| Resistance Level | $4.82 | $1.54 |
| Average True Range (ATR) | 0.22 | 0.14 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 89.92 | 12.99 |
Resources Connection Inc provides consulting and business initiative support services predominantly through its operative subsidiary, Resources Global Professionals. It has two segments RGP ( Resources Global Professionals.) and Sitrick. The RGP segment is focused on delivering consulting services catering to its client's operational needs and change initiatives utilizing a combination of bench and on-demand, talent. The Sitrick segment provides corporate, financial, transactional, and crisis communication and management services. The company generates a majority of its revenue from the RGP segment. Geographically, it derives its key revenue from North America and the rest from Europe and the Asia Pacific region.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.